Just fyi, this news is all over briefing.com. So we have that going for us.
Now the kicker. CDMO is currently the 2nd highest rated stock in the medical/biomed/biotech group in IBD's stock ranking. The med/biomed/biotech group is currently rated 55 out of the 197 groups IBD rates.
Might not mean much to other folks, but CDMO currently is carrying an A+ accumulation/distribution rating with an up/down volume of 2.4. To me, this is excellent and confirms what many of you have picked up on. It's hard to buy this stock at the current time.